| CWICX | LGCRX | CWICX / LGCRX | |
| Total Expense Ratio | 1.52 | 1.15 | 132% |
| Annual Report Gross Expense Ratio | 1.52 | 1.29 | 118% |
| Fund Existence | 24 years | 9 years | - |
| Gain YTD | 15.284 | 8.672 | 176% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 160B | 399M | 40,100% |
| Annual Yield % from dividends | 0.69 | 0.27 | 259% |
| Returns for 1 year | 20.46 | 20.27 | 101% |
| Returns for 3 years | 43.75 | 68.18 | 64% |
| Returns for 5 years | 34.41 | 41.49 | 83% |
| Returns for 10 years | 107.16 | N/A | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| VRLCX | 20.51 | 0.37 | +1.84% |
| Voya Large Cap Growth Port R6 | |||
| TSVRX | 22.01 | 0.33 | +1.52% |
| PGIM Quant Solutions Small-Cap Val R | |||
| BIPSX | 41.73 | 0.58 | +1.41% |
| ProFunds Biotechnology UltraSector Svc | |||
| OIERX | 27.63 | 0.06 | +0.22% |
| JPMorgan Equity Income R5 | |||
| CSHAX | 12.39 | 0.02 | +0.16% |
| NYLI Cushing® MLP Premier Class A | |||